213 related articles for article (PubMed ID: 14707065)
1. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
2. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
4. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
5. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
6. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma.
Wong CP; Levy R
Cancer Res; 2000 May; 60(10):2689-95. PubMed ID: 10825142
[TBL] [Abstract][Full Text] [Related]
7. Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo.
Gonthier M; Llobera R; Arnaud J; Rubin B
J Immunol; 2004 Dec; 173(11):7062-9. PubMed ID: 15557204
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.
Thirdborough SM; Radcliffe JN; Friedmann PS; Stevenson FK
Cancer Res; 2002 Mar; 62(6):1757-60. PubMed ID: 11912151
[TBL] [Abstract][Full Text] [Related]
9. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
10. TCR vaccines for active immunotherapy of T cell malignancies.
Okada CY; Wong CP; Denney DW; Levy R
J Immunol; 1997 Dec; 159(11):5516-27. PubMed ID: 9548492
[TBL] [Abstract][Full Text] [Related]
11. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection.
Yoneto T; Waki S; Takai T; Tagawa Yi ; Iwakura Y; Mizuguchi J; Nariuchi H; Yoshimoto T
J Immunol; 2001 May; 166(10):6236-41. PubMed ID: 11342646
[TBL] [Abstract][Full Text] [Related]
12. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine.
Salem ML; Kadima AN; Zhou Y; Nguyen CL; Rubinstein MP; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunol; 2004 May; 172(9):5159-67. PubMed ID: 15100252
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
14. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
15. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
17. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
[TBL] [Abstract][Full Text] [Related]
19. TCR alpha beta+ anti-tumor cytolytic T lymphocytes express NKR-P1 whilethe anti-tumor activity of TCR gamma delta+ T lymphocytes is not correlated to NKR-P1 expression.
Yrlid U; Petersson E; Dohlsten M; Hedlund G
Cell Immunol; 1996 Nov; 173(2):287-94. PubMed ID: 8912889
[TBL] [Abstract][Full Text] [Related]
20. Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.
Wolchok JD; Srinivasan R; Perales MA; Houghton AN; Bowne WB; Blachere NE
Cancer Immun; 2001 Aug; 1():9. PubMed ID: 12747770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]